Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Authors: Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo

Source: BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)

Subject Terms: Osimertinib, Real-world data, EGFR-activating mutations, T790M EGFR mutation, Second line, Non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d